Objective: We aimed to investigate the lipid-lowering efficacy of pitavastatin treatment in nondiabetic patients and patients with type 2 diabetes as well as the possible differences in diabetes regulation and treatment efficacy.

Material and Method: A total of 53 patients using only 2 mg of pitavastatin were included in our retrospective study. For examination the patients were divided into 4 groups. Those without a diagnosis of diabetes were the first group, those with a diabetes diagnosis and HbA1c values between 6% and 7.5% at both visits were the second group, those with HbA1c values above 7.5% at both visits were the third group, and those with HbA1c values were above 7.5% at the first visit. and below 7.5% at the second visit were determined as the fourth group. The lipid values, alanine transaminase (SGPT), aspartate transaminase (SGOT), and creatine phosphokinase (CPK) values of the patients in the groups were compared before and after treatment.

Results: The differences between the first and second visits (with percentages in parentheses) of the mean lipid values of the patients in the first, second, third and fourth groups were − 98.6 mg/dL (33.2%) (p<0.01), − 50.7 mg/dL (19.5%), − 52.2 mg/dL (21.7%), and − 58.2 mg/dL (23.3%) for total cholesterol; − 90 mg/dL (42.6%) (p<0.01), − 57.5 mg/dL (31.9%), − 55.4 mg/dL (34.8%), and − 64.9 mg/ dL (37.9%) for low-density lipoprotein (LDL) cholesterol. There was no significant change in SGPT, SGOT, or CPK levels in all of the groups. No adverse effects were noted that would terminate the pitavastatin-related treatment.

Conclusion: Moderate doses of pitavastatin provided effective and safe lipid control in nondiabetic patients and diabetic patients receiving antidiabetic therapy.

Pitavastatin Diabetes mellitus Hyperlipidemia